Crucial Contribution of BACH1 to Bladder Cancer Progression via Upregulating Epithelial‐Mesenchymal Transition Pathway
Cancer Science · 2026
DOI: 10.1111/cas.70284 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, 2026. Verfasst von Tomoya Hatayama und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan. Hauptthemen laut MEDLINE: Epithelial-Mesenchymal Transition, Basic-Leucine Zipper Transcription Factors, Urinary Bladder Neoplasms. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Bladder cancer (BC) is a prevalent urological malignancy, with muscle‐invasive subtypes exhibiting a particularly poor prognosis despite recent therapeutic advances. Established risk factors such as smoking contribute to carcinogenesis through the generation of reactive oxygen species, which trigger oxidative stress responses (OSRs). Broad‐complex‐Tramtrack‐Bric a brac and Cap'n' collar homology 1 (BACH1), a key transcription factor regulating OSRs, has been implicated in epithelial‐mesenchymal transition (EMT) and metastasis in several malignancies. This study aimed to clarify the role of BACH1 in BC progression and metastasis. Clinical analyses revealed that BACH1‐positive expression was correlated with aggressive tumor features, including advanced pathological stage, high tumor grade, and poor prognosis. In vitro experiments demonstrated that BACH1 knockdown suppressed, while overexpression enhanced, the invasive, migratory, and proliferative activities. RNA sequencing indicated significant enrichment of EMT‐related and cytokine‐driven immune pathways following BACH1 knockdown. Furthermore, in vivo mouse allograft experiments showed that Bach1 knockout cells exhibited reduced tumor growth and fewer lung metastases, accompanied by altered expression of EMT markers and modulation of cytokine‐driven immune signaling. Collectively, these findings suggest that BACH1 plays a crucial role in BC progression and metastasis, at least in part, through two complementary mechanisms, EMT activation and immune microenvironment modulation via cytokine signaling.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan.
- Department of Disease Model, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.
- Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.
ORCID-Profile: Tomoya Hatayama, Kenshiro Takemoto, Hiroyuki Shikuma, Yuki Kohada, Nobuyuki Hinata
Zitieren
APA
Hatayama, T., Takemoto, K., Kobatake, K., Miura, K., Perera, L. P., Yamanaka, R., Yukihiro, K., Shikuma, H., Iwane, K., Tasaka, R., Kohada, Y., Naito, M., Miyamoto, S., Sekino, Y., Kitano, H., Goto, K., Goriki, A., Hieda, K., Kaminuma, O., & Hinata, N. (2026). Crucial Contribution of BACH1 to Bladder Cancer Progression via Upregulating Epithelial‐Mesenchymal Transition Pathway. Cancer Science. https://doi.org/10.1111/cas.70284
Vancouver
Hatayama T, Takemoto K, Kobatake K, Miura K, Perera LP, Yamanaka R, et al. Crucial Contribution of BACH1 to Bladder Cancer Progression via Upregulating Epithelial‐Mesenchymal Transition Pathway. Cancer Science. 2026. doi:10.1111/cas.70284
BibTeX
@article{Hatayama2026,
author = {Hatayama, Tomoya and Takemoto, Kenshiro and Kobatake, Kohei and Miura, Kento and Perera, Liyanage P and Yamanaka, Ryoken and Yukihiro, Kazuma and Shikuma, Hiroyuki and Iwane, Kyosuke and Tasaka, Ryo and Kohada, Yuki and Naito, Miki and Miyamoto, Shunsuke and Sekino, Yohei and Kitano, Hiroyuki and Goto, Keisuke and Goriki, Akihiro and Hieda, Keisuke and Kaminuma, Osamu and Hinata, Nobuyuki},
title = {Crucial Contribution of BACH1 to Bladder Cancer Progression via Upregulating Epithelial‐Mesenchymal Transition Pathway},
journal = {Cancer Science},
year = {2026},
doi = {10.1111/cas.70284}
}
EUVIMED